CureVac’s Covid-19 vaccine induces immune response in study – Clinical Trials Arena

CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from 2 to 12µg and induced strong binding and neutralising antibody responses.
The Phase I study is evaluating the safety, reactogenicity and immunogenicity of the investigational vaccine CVnCoV, an optimised, non-chemically modified mRNA that encodes the prefusion stabilised full-length spike protein of the SARS-CoV-2 virus.
Its mode of action…

Click here to view the original article.